A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial Berk, M., Brook, S. and Trandafir, A. I. 1999, A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial, International clinical psychopharmacology, vol. 14, no. 3, pp. 177-180. Attached Files Name Description MIMEType Size Downloads Title A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial Author(s) Berk, M. orcid.org/0000-0002-5554-6946 Brook, S. Trandafir, A. I. Journal name International clinical psychopharmacology Volume number 14 Issue number 3 Start page 177 End page 180 Publisher Lippincott Williams & Wilkins Place of publication London, Eng. Publication date 1999-05 ISSN 0268-1315 Keyword(s) Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy Psychiatry PSYCHIATRY, SCI olanzapine psychosis schizophrenia Summary Little controlled data exist on the treatment of substance induced psychotic disorders. In this study, 30 patients meeting DSM-IV criteria for cannabis induced psychotic disorder were randomly allocated to receive either olanzapine or haloperidol in a 4-week double-blind clinical trial. There were no significant outcome differences between the two groups on any of the primary outcome measures, the Brief Psychiatric Rating Scale (haloperidol 25.7; olanzapine 27.1; P = 0.70); Clinical Global Impression (CGI) severity scale (haloperidol 1.8, olanzapine 2.3; P = 0.21) or the CGI improvement scale (haloperidol 1.3, olanzapine 1.7; P = 0.16). The haloperidol group however, developed significantly more extrapyramidal side-effects as measured by the Simpson Angus Scale (haloperidol 11.4, olanzapine 2.5; P = 0.014). Significantly (P = 0.027) more biperidin was used for extrapyramidal side-effects in the haloperidol (7.143 mg) than in the olanzapine (0.357 mg) group. Olanzapine appears to be as effective as haloperidol in the treatment of cannabis induced psychotic disorder, but is associated with a lower rate of extrapyramidal side-effects. Language eng Field of Research 0 Not Applicable Socio Economic Objective 0 Not Applicable HERDC Research category C1.1 Refereed article in a scholarly journal Copyright notice ©1999, Lippincott Williams & Wilkins Persistent URL http://hdl.handle.net/10536/DRO/DU:30071133 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to Elements publication management system Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Tue, 17 Mar 2015, 14:43:32 EST Wed, 18 Mar 2015, 04:18:17 EST Wed, 18 Mar 2015, 05:21:30 EST Fri, 05 Jun 2015, 15:28:55 EST Wed, 11 Jan 2017, 10:05:49 EST Thu, 13 Apr 2017, 12:13:03 EST Filtered Full Citation counts:   Cited 41 times in TR Web of Science Cited 40 times in Scopus Search Google Scholar Access Statistics: 100 Abstract Views, 1 File Downloads  -  Detailed Statistics Created: Tue, 17 Mar 2015, 14:43:32 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.